1. Home
  2. BEAM vs CPRI Comparison

BEAM vs CPRI Comparison

Compare BEAM & CPRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$31.65

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Capri Holdings Limited

CPRI

Capri Holdings Limited

HOLD

Current Price

$24.71

Market Cap

2.9B

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
CPRI
Founded
2017
1981
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Apparel
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
2.9B
IPO Year
2020
2011

Fundamental Metrics

Financial Performance
Metric
BEAM
CPRI
Price
$31.65
$24.71
Analyst Decision
Buy
Buy
Analyst Count
14
13
Target Price
$46.00
$27.08
AVG Volume (30 Days)
2.0M
2.1M
Earning Date
02-24-2026
02-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$55,701,000.00
$4,369,000,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$26.52
$2.07
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$13.53
$11.86
52 Week High
$36.44
$28.27

Technical Indicators

Market Signals
Indicator
BEAM
CPRI
Relative Strength Index (RSI) 56.44 45.79
Support Level $29.80 $24.17
Resistance Level $35.34 $26.26
Average True Range (ATR) 2.80 0.97
MACD 0.14 -0.13
Stochastic Oscillator 55.79 17.46

Price Performance

Historical Comparison
BEAM
CPRI

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About CPRI Capri Holdings Limited

Capri Holdings is a marketer, distributor, and retailer of upscale accessories and apparel in the Americas, Europe, and Asia. Michael Kors, Capri's original and largest brand by sales, offers handbags, footwear, and apparel through more than 700 company-owned stores, wholesale, and e-commerce. Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. Its products are sold in more than 200 company-operated stores. John Idol has served as Capri's CEO since 2003.

Share on Social Networks: